{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:24:00Z","timestamp":1793643840192,"version":"4.5.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Institute Grants","award":["5R01CA211913 and 5R01CA218026"],"award-info":[{"award-number":["5R01CA211913 and 5R01CA218026"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA272218"],"award-info":[{"award-number":["P50CA272218"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Standard preclinical human tumor models lack a human tumor stroma. However, as stroma contributes to therapeutic resistance, the lack of human stroma may make current models less stringent for testing new therapies. To address this, using patient-derived tumor cells, patient-derived cancer-associated mesenchymal stem\/progenitor cells, and human endothelial cells, we created a human stroma-patient-derived xenograft (HS-PDX) tumor model. HS-PDX, compared to the standard PDX model, demonstrates greater resistance to targeted therapy and chemotherapy and better reflect patient response to therapy. Furthermore, HS-PDX can be grown in mice with humanized bone marrow to create humanized immune stroma patient-derived xenograft (HIS-PDX) models. The HIS-PDX model contains human connective tissues, vascular and immune cell infiltrates. RNA sequencing analysis demonstrated a 94\u201396% correlation with primary human tumor. Using this model, we demonstrate the impact of human tumor stroma on recruitment of TAMs and tumor immune exclusion to impact to response to immunologic therapy. We show an immunosuppressive role for human tumor stroma and that this model can be used to identify immunotherapeutic combinations to overcome stroma-mediated immunosuppression. Combined, our data confirm a critical role for human stroma in therapeutic response and indicate that HIS-PDX can be an important tool for preclinical drug testing.<\/jats:p>","DOI":"10.1007\/s00262-026-04349-4","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:20:20Z","timestamp":1774354820000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A novel humanized immune stroma PDX cancer model for therapeutic studies"],"prefix":"10.1007","volume":"75","author":[{"given":"Dongli","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Beddows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoumei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Cascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy C.","family":"McGonigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin K.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyue","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tullia C.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Rinda","family":"Soong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose R.","family":"Conejo-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses T.","family":"Bility","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"Buckanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"4349_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Song E (2019) Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov 18:99\u2013115","journal-title":"Nat Rev Drug Discov"},{"key":"4349_CR2","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19:1423\u20131437","journal-title":"Nat Med"},{"key":"4349_CR3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrc1893","volume":"6","author":"AI Minchinton","year":"2006","unstructured":"Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583\u2013592","journal-title":"Nat Rev Cancer"},{"key":"4349_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrd3870","volume":"12","author":"DW McMillin","year":"2013","unstructured":"McMillin DW, Negri JM, Mitsiades CS (2013) The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 12:217\u2013228","journal-title":"Nat Rev Drug Discov"},{"key":"4349_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ccr.2012.02.017","volume":"21","author":"ES Nakasone","year":"2012","unstructured":"Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ et al (2012) Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21:488\u2013503","journal-title":"Cancer Cell"},{"key":"4349_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nm1699","volume":"14","author":"RJ Buckanovich","year":"2008","unstructured":"Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K et al (2008) Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 14:28\u201336","journal-title":"Nat Med"},{"key":"4349_CR7","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1182\/blood-2011-08-370908","volume":"119","author":"F Guilloton","year":"2012","unstructured":"Guilloton F, Caron G, M\u00e9nard C, Pangault C, Am\u00e9-Thomas P, Dulong J et al (2012) Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood 119:2556\u20132567","journal-title":"Blood"},{"key":"4349_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi5790","volume":"7","author":"S Cascio","year":"2021","unstructured":"Cascio S, Chandler C, Zhang L, Sinno S, Gao B, Onkar S et al (2021) Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by hedgehog inhibition. Sci Adv 7:eabi5790","journal-title":"Sci Adv"},{"key":"4349_CR9","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/nm.2454","volume":"17","author":"YS DeRose","year":"2011","unstructured":"DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT et al (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17:1514\u20131520","journal-title":"Nat Med"},{"key":"4349_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3095","volume":"14","author":"F Reyal","year":"2012","unstructured":"Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F et al (2012) Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res 14:R11","journal-title":"Breast Cancer Res"},{"key":"4349_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/978-1-0716-1956-8_17","volume":"2424","author":"SB Gitto","year":"2022","unstructured":"Gitto SB, George E, Medvedev S, Simpkins F, Powell DJ Jr. (2022) Humanized patient-derived xenograft models of ovarian cancer. Methods mol biol (Clifton, NJ) 2424:255\u2013274","journal-title":"Methods mol biol (Clifton, NJ)"},{"key":"4349_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00786-z","volume":"8","author":"H Jespersen","year":"2017","unstructured":"Jespersen H, Lindberg MF, Donia M, Soderberg EMV, Andersen R, Keller U et al (2017) Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nat Commun 8:707","journal-title":"Nat Commun"},{"key":"4349_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/978-1-4939-9145-7_15","volume":"1953","author":"LC Yao","year":"2019","unstructured":"Yao LC, Aryee KE, Cheng M, Kaur P, Keck JG, Brehm MA (2019) Creation of PDX-bearing humanized mice to study immuno-oncology. Methods mol biol (Clifton, NJ) 1953:241\u2013252","journal-title":"Methods mol biol (Clifton, NJ)"},{"key":"4349_CR14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/483531a","volume":"483","author":"CG Begley","year":"2012","unstructured":"Begley CG, Ellis LM (2012) Drug development: raise standards for preclinical cancer research. Nature 483:531\u2013533","journal-title":"Nature"},{"key":"4349_CR15","first-page":"114","volume":"6","author":"IW Mak","year":"2014","unstructured":"Mak IW, Evaniew N, Ghert M (2014) Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res 6:114\u2013118","journal-title":"Am J Transl Res"},{"key":"4349_CR16","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1172\/JCI45273","volume":"121","author":"K McLean","year":"2011","unstructured":"McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S et al (2011) Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest 121:3206\u20133219","journal-title":"J Clin Invest"},{"key":"4349_CR17","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1038\/nprot.2012.130","volume":"7","author":"J Beers","year":"2012","unstructured":"Beers J, Gulbranson DR, George N, Siniscalchi LI, Jones J, Thomson JA et al (2012) Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions. Nat Protoc 7:2029\u20132040","journal-title":"Nat Protoc"},{"key":"4349_CR18","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.stemcr.2014.09.005","volume":"3","author":"X Lian","year":"2014","unstructured":"Lian X, Bao X, Al-Ahmad A, Liu J, Wu Y, Dong W et al (2014) Efficient differentiation of human pluripotent stem cells to endothelial progenitors via small-molecule activation of WNT signaling. Stem Cell Rep 3:804\u2013816","journal-title":"Stem Cell Rep"},{"key":"4349_CR19","doi-asserted-by":"publisher","first-page":"12774","DOI":"10.1073\/pnas.1310675110","volume":"110","author":"R Samuel","year":"2013","unstructured":"Samuel R, Daheron L, Liao S, Vardam T, Kamoun WS, Batista A et al (2013) Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells. Proc Natl Acad Sci U S A 110:12774\u201312779","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4349_CR20","doi-asserted-by":"publisher","first-page":"e120430","DOI":"10.1172\/jci.insight.120430","volume":"3","author":"J Samal","year":"2018","unstructured":"Samal J, Kelly S, Na-Shatal A, Elhakiem A, Das A, Ding M et al (2018) Human immunodeficiency virus infection induces lymphoid fibrosis in the BM-liver-thymus-spleen humanized mouse model. JCI Insight 3:e120430","journal-title":"JCI Insight"},{"key":"4349_CR21","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.18632\/oncotarget.6870","volume":"7","author":"LG Coffman","year":"2016","unstructured":"Coffman LG, Choi YJ, McLean K, Allen BL, di Magliano MP, Buckanovich RJ (2016) Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4\/HH signaling loop. Oncotarget 7:6916\u20136932","journal-title":"Oncotarget"},{"key":"4349_CR22","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1016\/j.celrep.2019.02.032","volume":"26","author":"I Chefetz","year":"2019","unstructured":"Chefetz I, Grimley E, Yang K, Hong L, Vinogradova EV, Suciu R et al (2019) A Pan-ALDH1A inhibitor induces necroptosis in ovarian cancer stem-like cells. Cell Rep 26:3061\u20133075","journal-title":"Cell Rep"},{"key":"4349_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1158\/1078-0432.CCR-16-0492","volume":"23","author":"A Perales-Puchalt","year":"2017","unstructured":"Perales-Puchalt A, Svoronos N, Rutkowski MR, Allegrezza MJ, Tesone AJ, Payne KK et al (2017) Follicle-Stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target. Clin Cancer Res 23:441\u2013453","journal-title":"Clin Cancer Res"},{"key":"4349_CR24","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu Z, Eils R, Schlesner M (2016) Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32:2847\u20132849","journal-title":"Bioinformatics"},{"key":"4349_CR25","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1167\/iovs.02-1189","volume":"44","author":"D Yang","year":"2003","unstructured":"Yang D, Pan A, Swaminathan A, Kumar G, Hughes BA (2003) Expression and localization of the inwardly rectifying potassium channel Kir7.1 in native bovine retinal pigment epithelium. Invest Ophthalmol Vis Sci 44:3178\u20133185","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4349_CR26","doi-asserted-by":"publisher","first-page":"E2939","DOI":"10.1073\/pnas.1206400109","volume":"109","author":"SM McAuliffe","year":"2012","unstructured":"McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS et al (2012) Targeting notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A 109:E2939\u2013E2948","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4349_CR27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ygyno.2015.03.005","volume":"137","author":"I Diaz-Padilla","year":"2015","unstructured":"Diaz-Padilla I, Wilson MK, Clarke BA, Hirte HW, Welch SA, Mackay HJ et al (2015) A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret, Chicago and California phase II consortia. Gynecol Oncol 137:216\u2013222","journal-title":"Gynecol Oncol"},{"key":"4349_CR28","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.clbc.2017.08.008","volume":"18","author":"S Cid","year":"2018","unstructured":"Cid S, Eiro N, Fernandez B, Sanchez R, Andicoechea A, Fernandez-Muniz PI et al (2018) Prognostic influence of tumor stroma on breast cancer subtypes. Clin Breast Cancer 18:e123\u2013e133","journal-title":"Clin Breast Cancer"},{"key":"4349_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03348-z","volume":"9","author":"AM Givel","year":"2018","unstructured":"Givel AM, Kieffer Y, Scholer-Dahirel A, Sirven P, Cardon M, Pelon F et al (2018) miR200-regulated CXCL12beta promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. Nat Commun 9:1056","journal-title":"Nat Commun"},{"key":"4349_CR30","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.actbio.2022.03.044","volume":"144","author":"J Kim","year":"2022","unstructured":"Kim J, Park H, Kim H, Kim Y, Oh HJ, Chung S (2022) Microfluidic one-directional interstitial flow generation from cancer to cancer associated fibroblast. Acta Biomater 144:258\u2013265","journal-title":"Acta Biomater"},{"key":"4349_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09062-y","volume":"7","author":"LD Moore-Smith","year":"2017","unstructured":"Moore-Smith LD, Isayeva T, Lee JH, Frost A, Ponnazhagan S (2017) Silencing of TGF-beta1 in tumor cells impacts MMP-9 in tumor microenvironment. Sci Rep 7:8678","journal-title":"Sci Rep"},{"key":"4349_CR32","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41467-022-29366-6","volume":"13","author":"J Qi","year":"2022","unstructured":"Qi J, Sun H, Zhang Y, Wang Z, Xun Z, Li Z et al (2022) Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer. Nat Commun 13:1742","journal-title":"Nat Commun"},{"key":"4349_CR33","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6870","author":"LG Coffman","year":"2016","unstructured":"Coffman LG, Choi Y-J, McLean K, Allen BL, di Magliano MP, Buckanovich RJ (2016) Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4\/HH signaling loop. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.6870","journal-title":"Oncotarget"},{"key":"4349_CR34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.trsl.2016.03.016","volume":"175","author":"LG Coffman","year":"2016","unstructured":"Coffman LG, Burgos-Ojeda D, Wu R, Cho K, Bai S, Buckanovich RJ (2016) New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination. Transl Res 175:92\u2013102","journal-title":"Transl Res"},{"key":"4349_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ejvs.2017.10.012","volume":"55","author":"CG Wang","year":"2018","unstructured":"Wang CG, Li Y, Yang M, Zou YH, Liu HH, Liang ZY et al (2018) Efficient differentiation of bone marrow mesenchymal stem cells into endothelial cells in vitro. Eur J Vasc Endovasc Surg 55:257\u2013265","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"4349_CR36","doi-asserted-by":"publisher","first-page":"16891","DOI":"10.1073\/pnas.0404398101","volume":"101","author":"S Jiang","year":"2004","unstructured":"Jiang S, Walker L, Afentoulis M, Anderson DA, Jauron-Mills L, Corless CL et al (2004) Transplanted human bone marrow contributes to vascular endothelium. Proc Natl Acad Sci U S A 101:16891\u201316896","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4349_CR37","doi-asserted-by":"publisher","first-page":"6396","DOI":"10.1158\/0008-5472.CAN-16-0225","volume":"76","author":"S Bai","year":"2016","unstructured":"Bai S, Ingram P, Chen YC, Deng N, Pearson A, Niknafs YS et al (2016) EGFL6 regulates the asymmetric division, maintenance, and metastasis of ALDH+ ovarian cancer cells. Cancer Res 76:6396\u20136409","journal-title":"Cancer Res"},{"key":"4349_CR38","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1200\/JCO.2006.08.8583","volume":"25","author":"RJ Buckanovich","year":"2007","unstructured":"Buckanovich RJ, Sasaroli D, O\u2019Brien-Jenkins A, Botbyl J, Hammond R, Katsaros D et al (2007) Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 25:852\u2013861","journal-title":"J Clin Oncol"},{"key":"4349_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103666","volume":"28","author":"Z Peng","year":"2023","unstructured":"Peng Z, Li M, Li H, Gao Q (2023) PD-1\/PD-L1 immune checkpoint blockade in ovarian cancer: dilemmas and opportunities. Drug Discov Today 28:103666","journal-title":"Drug Discov Today"},{"key":"4349_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-019-0518-z","volume":"7","author":"A Capasso","year":"2019","unstructured":"Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL et al (2019) Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J Immunother Cancer 7:37","journal-title":"J Immunother Cancer"},{"key":"4349_CR41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam A, Prasad V (2019) Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2:e192535","journal-title":"JAMA Netw Open"},{"key":"4349_CR42","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/cam4.4456","volume":"11","author":"JJ Jiang","year":"2022","unstructured":"Jiang JJ, Ding YF, Chen YY, Lu J, Chen YR, Wu GH et al (2022) Pan-cancer analyses reveal that increased Hedgehog activity correlates with tumor immunosuppression and resistance to immune checkpoint inhibitors. Cancer Med-Us 11:847\u2013863","journal-title":"Cancer Med-Us"},{"key":"4349_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051107","author":"C Mehlman","year":"2021","unstructured":"Mehlman C, Takam Kamga P, Costantini A, Julie C, Dumenil C, Dumoulin J et al (2021) Baseline hedgehog pathway activation and increase of plasma Wnt1 protein are associated with resistance to immune checkpoint inhibitors in advanced non-small-cell lung cancer. Cancers. https:\/\/doi.org\/10.3390\/cancers13051107","journal-title":"Cancers"},{"key":"4349_CR44","doi-asserted-by":"publisher","first-page":"9881","DOI":"10.1021\/acsnano.8b02481","volume":"12","author":"J Zhao","year":"2018","unstructured":"Zhao J, Xiao ZL, Li TT, Chen HQ, Yuan Y, Wang YA et al (2018) Stromal modulation reverses primary resistance to immune checkpoint blockade in pancreatic cancer. ACS Nano 12:9881\u20139893","journal-title":"ACS Nano"},{"key":"4349_CR45","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1172\/JCI128644","volume":"129","author":"AJ Petty","year":"2019","unstructured":"Petty AJ, Li A, Wang X, Dai R, Heyman B, Hsu D et al (2019) Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment. J Clin Invest 129:5151\u20135162","journal-title":"J Clin Invest"},{"key":"4349_CR46","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1126\/sciadv.abi5790","volume":"7","author":"S Cascio","year":"2021","unstructured":"Cascio S, Candler CZ, Zhang L, Sarah S, Gao B, Onkar SB, Vignali TC, Dario AA, Haider M, Osmanbeyoglu HU, Vlad AM, Coffman LGB, Ronald J (2021) Cancer associated MSC drive tumor immune exclusion and resistance to immunotherapy which can be overcome by hedgehog inhibition. Sci Adv 7:5790","journal-title":"Sci Adv"},{"key":"4349_CR47","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.1158\/0008-5472.CAN-20-1723","volume":"81","author":"DC Hinshaw","year":"2021","unstructured":"Hinshaw DC, Hanna A, Lama-Sherpa T, Metge B, Kammerud SC, Benavides GA et al (2021) Hedgehog signaling regulates metabolism and polarization of mammary tumor-associated macrophages. Cancer Res 81:5425\u20135437","journal-title":"Cancer Res"},{"key":"4349_CR48","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.3389\/fonc.2019.01512","volume":"9","author":"SD Jayasingam","year":"2020","unstructured":"Jayasingam SD, Citartan M, Thang TH, Zin AAM, Ang KC, Ch\u2019ng ES (2020) Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice. Front Oncol 9:1512","journal-title":"Front Oncol"},{"key":"4349_CR49","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/nm0910-974","volume":"16","author":"LM Ellis","year":"2010","unstructured":"Ellis LM, Fidler IJ (2010) Finding the tumor copycat: therapy fails, patients don\u2019t. Nat Med 16:974\u2013975","journal-title":"Nat Med"},{"key":"4349_CR50","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrd1470","volume":"3","author":"I Kola","year":"2004","unstructured":"Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711\u2013715","journal-title":"Nat Rev Drug Discov"},{"key":"4349_CR51","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1002\/mc.22887","volume":"57","author":"JJ Morton","year":"2018","unstructured":"Morton JJ, Keysar SB, Perrenoud L, Chimed TS, Reisinger J, Jackson B et al (2018) Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer. Mol Carcinog 57:1651\u20131663","journal-title":"Mol Carcinog"},{"key":"4349_CR52","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/mc.23195","volume":"59","author":"JJ Morton","year":"2020","unstructured":"Morton JJ, Alzofon N, Jimeno A (2020) The humanized mouse: emerging translational potential. Mol Carcinog 59:830\u2013838","journal-title":"Mol Carcinog"},{"key":"4349_CR53","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila MR, de Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501:346\u2013354","journal-title":"Nature"},{"key":"4349_CR54","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1158\/0008-5472.CAN-13-0023","volume":"73","author":"TL Yeung","year":"2013","unstructured":"Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J et al (2013) TGF-beta modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res 73:5016\u20135028","journal-title":"Cancer Res"},{"key":"4349_CR55","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","volume":"22","author":"E Pujade-Lauraine","year":"2021","unstructured":"Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL et al (2021) Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol 22:1034\u20131046","journal-title":"Lancet Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04349-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04349-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04349-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:05:36Z","timestamp":1774357536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04349-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4349"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04349-4","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflict interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"117"}}